ImmunityBio, Inc. (NASDAQ: IBRX) reported Q4 EPS of ($0.06), $0.05 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $38.28 million versus the consensus estimate of $35.99 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.